- In January 2025, Luminex Corporation, a leading provider of multiplex assay technology, announced the launch of its next-generation xMAP INTELLIFLEX DR-SE System, designed to enhance the speed and sensitivity of multiplex assays. This new system offers improved dynamic range, enhanced multiplexing capability, and increased throughput, making it ideal for biomarker discovery, clinical diagnostics, and drug development. It supports both protein and nucleic acid analysis, enabling researchers to gain deeper insights into complex biological processes
- In October 2024, Bio-Rad Laboratories, Inc. introduced its new Bio-Plex Pro Human Cytokine Screening Panel, a high-sensitivity multiplex immunoassay that enables the simultaneous detection of multiple cytokines and chemokines in a single sample. This innovative panel supports biomarker research, immuno-oncology studies, and personalized medicine, providing researchers with a powerful tool for disease profiling and patient stratification
- In September 2024, Thermo Fisher Scientific launched its latest Invitrogen QuantiGene Plex Assay, a customizable bead-based multiplex assay platform that enables the simultaneous measurement of multiple RNA targets. This new platform is designed to deliver high sensitivity and specificity, supporting applications in gene expression analysis, pathway analysis, and clinical research
- In September 2024, Qiagen introduced the QIAxcel Advanced System, an automated, high-throughput multiplex assay platform that streamlines the analysis of nucleic acids for research and diagnostic applications. This system offers superior accuracy and reproducibility, supporting a wide range of applications, including oncology, infectious disease testing, and biomarker discovery
